Cancer Immunotherapy: Managing Amino Acids during Forced Aetopy| Stephy Publishers
SOJ Pediatrics and Clinical Neonatology - (SOJPCN)| Stephy Publishers
Abstract
Cancer patients of all ages
experience great satisfaction with initial positive results from first-line
therapy. Adjuvant therapy helps decrease the risk of cancer recurring or
metastasizing. This review discusses forced atopy as cancer immunotherapy and explores
managing select amino acids to starve metastatic cells during forced atopy
(many allergies).
Introduction
A common goal in
oncology is a treatment protocol that minimizes risk and maximizes success. The
overall survival rate of children with solid tumor metastasis (Stage IV) has
shown little improvement in that the extent of the relocation of metastatic
cells, and their progression, is not well understood. To better understand the
limits of metastasis, an alternative treatment strategy is proposed; based on
maladaptive immunity. A skin cream having natural and recombinant allergens,
and associated with immunologic adjuvants, is vectored into the cancer patient
by topical dermal absorption. After that, humoral immunity increases the
expression of cross-reactive immunoglobulin-E (IgE) primed effector cells,
designed to decrease the incidence and prevalence of endogenous proteins that
support the metastatic environment.1
Cancer recurrence or
metastasis after first-line therapies is life-threatening. In metastasis,
metastatic cells from a primary tumor spread throughout the body, forming
secondary tumors that aggressively grow and often cause death. Approximately
90% of cancer deaths are due to metastasis.2
https://www.stephypublishers.com/sojpcn/fulltext/SOJPCN.MS.ID.000506.php
More #Openaccessjournals
https://www.stephypublishers.com/
Comments
Post a Comment